President
Tris Pharma, Inc.
Monmouth Junction, New Jersey
James Hackworth, Ph.D., has over 15 years of multi-therapeutic area experience domestically and internationally with an extensive track record in licensing, M&A and partnership transactions, particularly those with a high degree of complexity; pharmaceutical commercialization; and drug development. Currently, he is President of Tris Pharma’s Brand Division, overseeing the commercialization of the company’s ADHD drugs and leading the development of products for pain, psychiatry and neurology. Prior to that he founded and was President of Park Therapeutics until it was acquired by Tris in April 2021. Prior to founding Park, James held the position of Sr. Vice President, Corporate Development and Commercialization Strategy at Shionogi where he launched Symproic and Mulpleta and prepared the launches of Fetroja and Xofluza, the latter in partnership with Roche. James began his career as a consultant at McKinsey and Company and holds a Ph.D. in Physics from Columbia University and a B.S. in Physics from The Ohio State University.
Disclosure information not submitted.